Perspectives on Chronic Kidney Disease With Type 2 Diabetes and Risk Management: Practical Viewpoints and a Paradigm Shift Using a Pillar Approach.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
   Trial
2. Continuous Glucose Monitoring and Long-Term Glycemic and Kidney Outcomes.JAMA network open · 2026
   Article
3. Ferroptosis-related proteins ALOX15 and HMOX1 are upregulated and associated with inflammation in patients with diabetic nephropathy: a prospective cross-sectional study.International urology and nephrology · 2026
   Article
4. Metabolic Memory-Mediated Epigenetic Regulation of EMT in Diabetic Kidney Disease: Mechanisms and Therapeutic Implications.International journal of molecular sciences · 2026
   Review
5. Causal effects of gut microbiota on diabetic kidney disease: insights from 16S rRNA sequencing and bidirectional Mendelian randomization.Renal failure · 2025
   Article
6. Estimated Glomerular Filtration Rate and Incident Prediabetes Risk in Normoglycemic Adults With Parental Type 2 Diabetes.Journal of the Endocrine Society · 2025
   Article
7. Pillar Risk-Based Treatment for Chronic Kidney Disease in People With Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
   Review
8. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025
   Review
9. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
   Review
10. Proteomic and metabolomic profiling reveals the underlying molecular mechanisms in modified alternate-day fasting-mediated protection against Diabetic kidney disease.PloS one · 2025
    Article
11. A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond.Electrolyte & blood pressure : E & BP · 2024
    Review
12. Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.BMC nephrology · 2024 · on this map
    Review
13. Tonabersat suppresses priming/activation of the NOD-like receptor protein-3 (NLRP3) inflammasome and decreases renal tubular epithelial-to-macrophage crosstalk in a model of diabetic kidney disease.Cell communication and signaling : CCS · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.